Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABIO NASDAQ:CLYM NASDAQ:CRDF NASDAQ:MCRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABIOARCA biopharma$384.99$1.56▼$4.49$34.82M0.91607,995 shs290,800 shsCLYMClimb Bio$2.01-1.5%$1.86$1.05▼$8.60$138.24M-0.05528,393 shs422,917 shsCRDFCardiff Oncology$2.00-2.0%$2.80$1.90▼$5.64$135.71M1.281.02 million shs732,783 shsMCRBSeres Therapeutics$17.40+10.9%$16.04$6.53▼$24.67$137.36M0.15241,907 shs154,360 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABIOARCA biopharma0.00%0.00%0.00%0.00%0.00%CLYMClimb Bio-1.47%-15.55%+5.79%+63.41%+200,999,900.00%CRDFCardiff Oncology-1.96%-6.10%-18.03%-33.77%-22.18%MCRBSeres Therapeutics+10.90%-6.70%+4.25%+125.10%-14.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABIOARCA biopharma$384.99$1.56▼$4.49$34.82M0.91607,995 shs290,800 shsCLYMClimb Bio$2.01-1.5%$1.86$1.05▼$8.60$138.24M-0.05528,393 shs422,917 shsCRDFCardiff Oncology$2.00-2.0%$2.80$1.90▼$5.64$135.71M1.281.02 million shs732,783 shsMCRBSeres Therapeutics$17.40+10.9%$16.04$6.53▼$24.67$137.36M0.15241,907 shs154,360 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABIOARCA biopharma0.00%0.00%0.00%0.00%0.00%CLYMClimb Bio-1.47%-15.55%+5.79%+63.41%+200,999,900.00%CRDFCardiff Oncology-1.96%-6.10%-18.03%-33.77%-22.18%MCRBSeres Therapeutics+10.90%-6.70%+4.25%+125.10%-14.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABIOARCA biopharma 0.00N/AN/AN/ACLYMClimb Bio 3.33Buy$9.00347.76% UpsideCRDFCardiff Oncology 2.80Moderate Buy$10.63431.25% UpsideMCRBSeres Therapeutics 1.75Reduce$73.67323.37% UpsideCurrent Analyst Ratings BreakdownLatest ABIO, CLYM, MCRB, and CRDF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025CLYMClimb BioBaird R WSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/15/2025CLYMClimb BioRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$9.008/6/2025CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $10.007/8/2025CRDFCardiff OncologyLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$19.006/24/2025CRDFCardiff OncologyJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold$3.506/18/2025CRDFCardiff OncologyWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABIOARCA biopharmaN/AN/AN/AN/A$2.25 per shareN/ACLYMClimb BioN/AN/AN/AN/A$3.15 per shareN/ACRDFCardiff Oncology$680K195.68N/AN/A$1.86 per share1.08MCRBSeres Therapeutics$126.32M1.21N/AN/A$1.61 per share10.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABIOARCA biopharma-$5.34M-$0.42N/AN/AN/AN/A-20.18%-19.51%N/ACLYMClimb Bio-$73.90M-$0.70N/AN/AN/AN/A-23.10%-22.47%11/11/2025 (Estimated)CRDFCardiff Oncology-$45.43M-$0.87N/AN/AN/A-9,344.14%-77.94%-63.65%11/6/2025 (Estimated)MCRBSeres Therapeutics$140K-$4.60N/AN/AN/AN/A-350.16%-67.69%11/12/2025 (Estimated)Latest ABIO, CLYM, MCRB, and CRDF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025CLYMClimb Bio-$0.19-$0.13+$0.06-$0.13N/AN/A8/6/2025Q2 2025MCRBSeres Therapeutics-$2.72-$2.27+$0.45-$2.27$11.75 millionN/A7/29/2025Q2 2025CRDFCardiff Oncology-$0.19-$0.21-$0.02-$0.21$0.11 million$0.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABIOARCA biopharmaN/AN/AN/AN/AN/ACLYMClimb BioN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABIOARCA biopharmaN/A26.6126.61CLYMClimb BioN/A14.0814.08CRDFCardiff OncologyN/A4.424.42MCRBSeres TherapeuticsN/A1.571.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABIOARCA biopharma56.44%CLYMClimb Bio69.76%CRDFCardiff Oncology16.29%MCRBSeres Therapeutics59.34%Insider OwnershipCompanyInsider OwnershipABIOARCA biopharma30.90%CLYMClimb Bio3.20%CRDFCardiff Oncology7.70%MCRBSeres Therapeutics4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABIOARCA biopharma614.51 million10.02 millionOptionableCLYMClimb Bio967.76 million65.60 millionN/ACRDFCardiff Oncology2066.53 million61.40 millionOptionableMCRBSeres Therapeutics3308.75 million8.34 millionOptionableABIO, CLYM, MCRB, and CRDF HeadlinesRecent News About These CompaniesSeres Therapeutics (NASDAQ:MCRB) Share Price Crosses Above 50 Day Moving Average - What's Next?September 14 at 5:08 AM | marketbeat.comAll You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to BuySeptember 9, 2025 | zacks.comBiggest stock movers Monday: RAPP, MCRB, SATS, QS, SMMT and moreSeptember 8, 2025 | msn.comSeres Therapeutics soars on report of takeover offerSeptember 8, 2025 | msn.comCharles Schwab Investment Management Inc. Sells 31,718 Shares of Seres Therapeutics, Inc. $MCRBSeptember 5, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?August 30, 2025 | marketbeat.comSeres Therapeutics (MCRB)'s Technical Outlook is Bright After Key Golden CrossAugust 28, 2025 | zacks.comSeres Therapeutics to Present Company Overview at H.C. Wainwright Global Investment Conference on September 8, 2025August 27, 2025 | quiverquant.comQSeres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment ConferenceAugust 27, 2025 | globenewswire.comSeres Therapeutics’ Earnings Call: Progress Amid ChallengesAugust 16, 2025 | theglobeandmail.comSeres Therapeutics Reports Q2 Results and Leadership ChangeAugust 8, 2025 | theglobeandmail.comSeres (MCRB) Q2 Loss Narrows 34%August 6, 2025 | fool.comSeres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | seekingalpha.comSeres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 6, 2025 | globenewswire.comSeres Therapeutics: Speculative Gem Backed By SER‑155 FDA BreakthroughJuly 31, 2025 | seekingalpha.comSeres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025July 22, 2025 | globenewswire.comSeres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual MeetingMay 27, 2025 | globenewswire.comSeres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?May 23, 2025 | zacks.comWall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to TradeMay 16, 2025 | zacks.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call TranscriptMay 9, 2025 | insidermonkey.comChardan Capital Downgrades Seres Therapeutics (MCRB)May 9, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABIO, CLYM, MCRB, and CRDF Company DescriptionsARCA biopharma NASDAQ:ABIOARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.Climb Bio NASDAQ:CLYM$2.01 -0.03 (-1.47%) As of 09/16/2025 04:00 PM EasternClimb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.Cardiff Oncology NASDAQ:CRDF$2.00 -0.04 (-1.96%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$2.05 +0.05 (+2.50%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Seres Therapeutics NASDAQ:MCRB$17.40 +1.71 (+10.90%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$17.46 +0.06 (+0.34%) As of 05:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
